For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and the formulated version represents a true change. These innovative therapies protect the transthyretin protein, halting its damaging build-up and alleviating the severity